At the scientific symposium "A Revolution with Biosimilars," organized by the Vietnam Cancer Association and Pfizer Vietnam on March 6-7, 2026, in Hanoi and Ho Chi Minh City, experts discussed ...
The FDA is doubling down on its goal to increase biosimilar drug availability in the U.S. | The FDA's newest draft guidance reinforces its previous commitment to streamlining biosimilar drug ...
The US Food and Drug Administration is easing some requirements for drugmakers developing copycat versions of costly biologic ...
The U.S. Food and Drug Administration plans to ease testing requirements for companies developing biosimilar drugs, aiming to make it simpler and faster to bring lower‑cost alternatives to ...
The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, ...
Nandita Vijayasimha, Bengaluru Tuesday, March 10, 2026, 08:00 Hrs [IST] ...
Celltrion said Monday it continues to see solid prescription growth across Asian markets, with several of its key biosimilar ...
There is growing concern that the FDA is shunning advisory committees that allow agency leaders, drugmakers, patients, and doctors to speak their minds in public ...
FDA plans to ease biosimilar study requirements, cutting development costs by ~$20M and boosting competition for costly biologics.
Cardinal Health (NYSE: CAH) today released its 2026 Biosimilars Report: Driving access and patient outcomes in physician ...
Modernizing biomanufacturing methods and reducing regulatory burdens are key landmarks on India’s roadmap for expanding biosimilars development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results